---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-027330"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:46:48.684899+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology receives FDA Fast Track for PYX-201 in head and neck cancer

## Summary
- FDA granted Fast Track Designation to PYX-201 for recurrent/metastatic HNSCC after prior chemo and anti-PD-(L)1.
- PYX-201 is a first-in-concept ADC targeting Extradomain-B Fibronectin in the tumor extracellular matrix.
- CEO Lara Sullivan called the designation a significant milestone and said trial recruitment is ongoing.
- Fast Track aims to speed development and review for serious conditions with unmet medical need.

## SEC filing metadata
- accession: 0000950170-25-027330
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017025027330/0000950170-25-027330-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017025027330/pyxs-20250225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-027330
- JSON: https://secwatch.observer/filing/0000950170-25-027330.json
- Plain text: https://secwatch.observer/filing/0000950170-25-027330.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.